10
Choi criteria will be used for response endpoints –Tumor size decrease of >10% or tumor density decrease of >15% RECIST will be recorded for all patients BMS (Dasatinib) in GIST: Evaluations

11
Two-arm phase IIa trial to simultaneously monitor safety and efficacy. A 20% response rate with less than a 15% rate of toxicity is targeted. Trial is terminated early if toxicity is high or efficacy is low. BMS (Dasatinib) in GIST: Design